Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.82 Insider Own80.13% Shs Outstand55.14M Perf Week54.19%
Market Cap1.03B Forward P/E- EPS next Y- Insider Trans0.02% Shs Float10.97M Perf Month32.34%
Income-42.55M PEG- EPS next Q- Inst Own8.65% Short Float22.79% Perf Quarter155.92%
Sales0.00M P/S- EPS this Y- Inst Trans-14.02% Short Ratio9.70 Perf Half Y120.14%
Book/sh0.66 P/B28.28 EPS next Y- ROA-71.28% Short Interest2.50M Perf Year162.43%
Cash/sh0.63 P/C29.42 EPS next 5Y- ROE-332.14% 52W Range3.78 - 17.05 Perf YTD51.80%
Dividend Est.- P/FCF- EPS past 5Y16.76% ROI-96.51% 52W High8.97% Beta1.78
Dividend TTM- Quick Ratio7.06 Sales past 5Y-30.13% Gross Margin- 52W Low391.53% ATR (14)1.50
Dividend Ex-Date- Current Ratio7.06 EPS Y/Y TTM43.33% Oper. Margin0.00% RSI (14)76.14 Volatility15.68% 10.25%
Employees56 Debt/Eq0.25 Sales Y/Y TTM-100.00% Profit Margin- Recom3.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q29.91% Payout- Rel Volume1.78 Prev Close16.13
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 07 AMC Avg Volume257.61K Price18.58
SMA2053.21% SMA5070.32% SMA200116.28% Trades Volume458,188 Change15.19%
Date Action Analyst Rating Change Price Target Change
Jul-27-21Initiated Stephens Overweight $28
Mar-11-21Initiated Maxim Group Buy $40
Jan-26-21Reiterated H.C. Wainwright Buy $16 → $40
May-12-20Upgrade H.C. Wainwright Neutral → Buy $6 → $16
Feb-14-20Downgrade H.C. Wainwright Buy → Neutral $26 → $6
Feb-25-19Initiated H.C. Wainwright Buy $27
Jul-09-24 07:27AM
Jul-08-24 08:00AM
Jul-03-24 02:44PM
Jun-28-24 08:00AM
08:00AM Loading…
Jun-04-24 08:00AM
May-20-24 05:39PM
May-17-24 06:41AM
May-16-24 08:00AM
May-14-24 05:17PM
May-13-24 09:02AM
May-09-24 08:00AM
May-08-24 06:06AM
03:56AM Loading…
May-07-24 09:56PM
May-02-24 08:00AM
Apr-28-24 11:59AM
Apr-24-24 04:05PM
Apr-01-24 04:19PM
Mar-29-24 06:30AM
Mar-28-24 10:53PM
Mar-14-24 04:05PM
Mar-08-24 01:17PM
08:00AM Loading…
Feb-14-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Dec-20-23 08:00AM
Nov-21-23 08:00AM
Nov-15-23 04:05PM
Nov-14-23 12:52PM
Nov-13-23 11:13AM
Nov-10-23 04:56PM
Oct-30-23 04:05PM
Oct-24-23 08:00AM
Oct-02-23 08:00AM
Sep-29-23 08:00AM
Sep-27-23 08:00AM
Sep-07-23 04:05PM
Aug-24-23 04:05PM
Aug-17-23 09:31AM
Aug-11-23 06:28AM
Aug-10-23 04:05PM
Jul-30-23 09:35AM
Jul-27-23 04:05PM
May-22-23 09:30AM
May-18-23 07:00AM
May-16-23 12:01PM
May-12-23 07:43AM
May-11-23 04:05PM
May-10-23 09:29AM
May-03-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:05PM
Apr-20-23 06:04AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-10-23 08:30AM
Mar-02-23 04:05PM
Feb-02-23 08:00AM
Dec-10-22 07:24AM
Nov-10-22 04:05PM
Oct-27-22 04:05PM
Oct-14-22 06:17AM
Oct-06-22 08:00AM
Oct-01-22 08:50AM
Sep-26-22 10:00AM
Sep-21-22 10:03AM
Sep-20-22 04:26PM
Aug-10-22 05:25PM
Aug-04-22 08:00AM
Jul-27-22 04:05PM
Jun-16-22 04:15PM
Jun-09-22 04:43PM
Jun-03-22 08:00AM
May-19-22 08:00AM
May-13-22 01:44PM
May-11-22 06:05PM
May-04-22 08:00AM
Apr-28-22 08:00AM
Apr-26-22 08:00AM
Apr-14-22 04:05PM
Mar-31-22 05:25PM
Mar-21-22 04:05PM
Mar-17-22 06:57AM
Feb-15-22 08:00AM
Feb-08-22 12:37PM
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barrett Burke ThomasPresident and CEOMay 20 '24Buy8.5610,00085,60010,000May 22 02:07 PM
DUGGAN ROBERT WDirectorDec 12 '23Buy9.1517,999164,69136,984,179Dec 14 07:37 PM
DUGGAN ROBERT WDirectorDec 11 '23Buy9.3690,118843,50436,966,180Dec 13 06:03 PM
DUGGAN ROBERT WDirectorDec 08 '23Buy9.54116,6561,112,89836,876,062Dec 12 07:28 PM
DUGGAN ROBERT WDirectorDec 07 '23Buy9.1974,852687,89036,759,406Dec 11 08:13 PM
DUGGAN ROBERT WDirectorDec 06 '23Option Exercise5.959,93359,10136,601,741Dec 08 07:38 PM
DUGGAN ROBERT WDirectorDec 06 '23Buy9.0682,813750,28636,684,554Dec 08 07:38 PM
DUGGAN ROBERT WDirectorDec 05 '23Buy9.3466,021616,636351,565Dec 07 08:34 PM
DUGGAN ROBERT WDirectorDec 04 '23Option Exercise10.6640,347430,09936,591,808Dec 06 07:54 PM
DUGGAN ROBERT WDirectorDec 04 '23Buy10.3827,000280,260285,544Dec 06 07:54 PM
DUGGAN ROBERT WDirectorDec 01 '23Buy9.0745,600413,592258,544Dec 05 08:31 PM
DUGGAN ROBERT WDirectorNov 30 '23Buy9.06152,9441,385,673212,944Dec 04 07:37 PM
DUGGAN ROBERT WDirectorNov 29 '23Option Exercise5.951,6679,91936,392,861Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 29 '23Buy9.44158,6001,497,18436,551,461Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 29 '23Buy9.2160,000552,60060,000Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 28 '23Buy8.98124,3971,117,08536,391,194Nov 30 07:25 PM
DUGGAN ROBERT WDirectorNov 17 '23Buy6.1020,241123,47036,266,797Nov 20 08:56 PM
Danahy Kevin PatrickChief Executive OfficerNov 16 '23Buy6.525,39335,15635,887Nov 17 09:11 AM
Levinson Mitchell E.Chief Strategy OfficerNov 15 '23Buy5.9113,53980,0589,135Nov 17 09:10 AM
Levinson Mitchell E.Chief Strategy OfficerNov 15 '23Buy5.874,26125,03373,027Nov 17 09:10 AM
Zanganeh MahkamDirectorNov 13 '23Option Exercise2.1476,075162,800604,911Nov 15 05:37 PM
DUGGAN ROBERT WDirectorNov 07 '23Option Exercise5.9513,26578,92736,246,556Nov 09 06:32 PM
DUGGAN ROBERT WDirectorAug 25 '23Option Exercise5.951,6679,91936,233,291Aug 28 08:08 PM
DUGGAN ROBERT WDirectorJul 25 '23Option Exercise5.951,6679,91936,231,624Jul 27 09:09 AM